Bio-Techne (TECH) Proxy filing summary

Executive summary

• Merger agreement signed for acquisition by Merck KGaA, Darmstadt, Germany, with closing expected by late 2026 or early 2027, pending regulatory and shareholder approvals.

• Integration planning underway, focusing on business continuity, talent retention, and leveraging combined strengths.

• Until closing, both companies operate independently, with no immediate operational changes.

• Forward-looking statements highlight risks including regulatory approvals, integration challenges, and market uncertainties.

Voting matters and shareholder proposals

• Shareholder approval is a key closing condition for the transaction.

• Proxy materials and relevant documents are filed with the SEC and available for shareholder review.

Board of directors and corporate governance

• Directors and executive officers of both companies may participate in proxy solicitation.

• Information on directors, governance, and compensation is available in prior proxy statements and SEC filings.